ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 0080 • ACR Convergence 2024

    Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27

    Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)

    Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
  • Abstract Number: 0564 • ACR Convergence 2024

    The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study

    Mayas Arraf1, Devy Zisman2, walid Saliba3, Nili Stein4 and Joy Feld5, 1Technion medical school, Haifa, Israel, 2Carmel Medical Center, Haifa, Israel, 3Carmel medical center, Haifa, Israel, 4Department of Community Medicine and Epidemiology, Haifa, Israel, 5Carmel and Zvulun Medical Centre, Haifa, Israel

    Background/Purpose: Scarce data exist regarding the incidence of venous thromboembolism events (VTE); pulmonary embolism (PE) and deep vein thrombosis (DVT), in patients with axial spondylarthritis…
  • Abstract Number: 1030 • ACR Convergence 2024

    Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region

    Mathieu Choufani1, Wissam Ghusn2 and Joerg Ermann3, 1Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, 2Department of Internal Medicine, Boston Medical Center, Boston, MA, 3Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: While axial spondyloarthritis (AxSpA) was historically perceived as a "white man's disease", it is now appreciated as a condition that can affect individuals of…
  • Abstract Number: 1459 • ACR Convergence 2024

    Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity

    Michael Nissen1, Adrian Ciurea2, Raphael Micheroli3, Eric Trunk4 and Delphine Courvoisier5, 1Geneva University Hospital, Geneva, Switzerland, 2University Hospital Zurich, Zürich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4Geneva University Hospital, Geenva, Switzerland, 5University Hospitals of Geneva, Geneva, Switzerland

    Background/Purpose: Current EULAR recommendations highlight the importance of a healthy, balanced diet in patients with inflammatory rheumatic disease, including axial spondylarthritis (axSpA). A Mediterranean-style diet…
  • Abstract Number: 2119 • ACR Convergence 2024

    IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures

    Chloe Heiting1, Donald McMahon1, Douglas Mintz1, Weijia Yuan1, Insa Mannstadt1, Linda A Russell1, Emily Stein1, Dalit Ashany2 and Susan Goodman3, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Scarsdale, NY, 3Hospital for Special Surgery, New York 10025, NY

    Background/Purpose: Axial spondyloarthritis (AxSpA) is characterized by abnormal bone formation and, paradoxically, bone loss accompanied by increased bone fragility and vertebral fracture risk. Tumor necrosis…
  • Abstract Number: 0081 • ACR Convergence 2024

    The Axial Spondyloarthritis Risk Variant CARD9 S12N Enhances Neutrophil-mediated Th Responses

    Hillary Struthers1, Kofi Asare-Konadu2, Emily Vance1 and Ruth Napier3, 1Oregon Health & Science University, Portland, OR, 2Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, 3Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR

    Background/Purpose: Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the entheses of the spine and/or sacroiliac joints. The cause of axSpA…
  • Abstract Number: 0565 • ACR Convergence 2024

    Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study

    Anthony Lichaa1, Pauline KRUG1 and Adrien Nzeusseu Toukap2, 1Cliniques universitaires St-Luc, Brussel, Belgium, 2Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium

    Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
  • Abstract Number: 1054 • ACR Convergence 2024

    Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review

    Keri Geinosky1, Joel Thompson2, Joshua Torrey3 and Louise Thoma4, 1University of North Carolina at Chapel Hill, Chapel Hill, 2university of north carolina - chapel hill, Cary, NC, 3UNC Chapel Hill, Westmoreland, NH, 4University of North Carolina, Chapel Hill, NC

    Background/Purpose: Rehabilitation services, such as physical therapy (PT) and occupational therapy (OT), are recommended in the care of inflammatory arthritis and other rheumatic conditions. However, the…
  • Abstract Number: 1475 • ACR Convergence 2024

    Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial

    Raj Sengupta1, Pedro M Machado2, Philippe Goupille3, Victoria Navarro Compán4, Huji Xu5, mohamed sheesh6, Khai Jing Ng7, Marcus Ngantcha8, Hagen Russ9, Gabriel Doridot6 and Xenofon Baraliakos10, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, 3UPR CNRS 4301 CBM, NMNS, University of Tours; Department of Rheumatology, University hospital, Tours, Tours, France, 4La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 5Changzheng Hospital, Naval Medical University, Shanghai, China, Shanghai, China (People's Republic), 6Eli Lilly, Indianopolis, IN, 7Eli Lilly and Company, Madrid, Spain, 8Eli Lilly and Company, Indianapolis, IN, 9Eli Lilly, Indianopolis, 10Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Elevated baseline (BL) C-reactive protein (CRP) level can serve as a predictor for treatment response to TNF inhibitors in patients (pts) with r-axSpA. The…
  • Abstract Number: 2138 • ACR Convergence 2024

    DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis

    Edgar Wiebe1, Elisa Schilling2, Dörte Huscher2, Zhivana Boydzhieva3, andriko Palmowski4, Sandra Hermann5, burkhard Muche5, Gerhard Krönke5 and FRANK HARTMUT DR. BUTTGEREIT1, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité-Universitätsmedizin Berlin, Berlin, Germany, 3Charité Universittsmedizin, Berlin, Germany, 4Charité - Universittsmedizin Berlin, Berlin, Germany, 5Rheumatology, Charité, Berlin, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis and fragility fracture risk that may not be reflected by areal bone mineral density (aBMD) measurements alone.…
  • Abstract Number: 0083 • ACR Convergence 2024

    Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice

    Mariia Korshko1, Shaghayegh Foroozan Boroojeni2 and Nigil Haroon3, 1University Health Network, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease affecting both the joints and gut, with 60% of patients showing microscopic and 10% overt IBD…
  • Abstract Number: 0570 • ACR Convergence 2024

    Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients

    Halah Alfatlawi1, abdulmajeed alharbi2, eun seo kwak2, rawnag el sheikh2 and nezam altorok2, 1the university of toledo, Toledo, OH, 2the university of toledo, Toledo

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…
  • Abstract Number: 1248 • ACR Convergence 2024

    Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis

    Shilpa Venkatachalam1, Jeffrey Curtis2, Anne Sydor3, Erik Stone4, Angela Degrassi3, Esteban Rivera5, Laura Stradford6 and Kelly Gavigan3, 1Global Healthy Living Foundation, New York, NY, 2University of Alabama at Birmingham, Hoover, AL, 3Global Healthy Living Foundation, Upper Nyack, NY, 4Global Healthy Living Foundation, Upper Nyack, 5Global Healthy Living Foundation, Long Island City, NY, 6Global Healthy Living Foundation, Nyack, NY

    Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
  • Abstract Number: 1476 • ACR Convergence 2024

    Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis

    Mark Hwang1, Seokhun Kim2, Shervin Assassi3, Joyce Samuel4, Charles Green2, Jon Tyson4 and John Reveille5, 1Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, 2UTHealth Houston, Houston, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4UTHealth Houston, Houston, TX, 5UTHealth Houston Division of Rheumatology, Houston

    Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line pharmacological treatment for Axial Spondyloarthritis (axSpA), yet individual responses to different NSAIDs vary significantly. This study aims…
  • Abstract Number: 2156 • ACR Convergence 2024

    Differential Item Functioning of Inflammatory Back Pain Criteria in US Subpopulations

    Mark Hwang1, Seokhun Kim2, Shervin Assassi3, Alexis Ogdie4, Michael Weisman5, John Reveille6 and Charles Green2, 1Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, 2UTHealth Houston, Houston, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Stanford University, Los Angeles, CA, 6UTHealth Houston Division of Rheumatology, Houston

    Background/Purpose: IInflammatory back pain (IBP) has clinical features that distinguish it from other back pain etiologies.  While there are established IBP criteria, in different subpopulations…
  • 1
  • 2
  • 3
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology